Abstract

Abstract Genetically targeted therapies have proven to be a successful approach to treating cancer because they inhibit the causal (driver) biology of tumors that is absent in healthy cells. While targeted therapies exist for most oncogenes, only a small fraction of loss-of-function (LoF) tumor suppressor genes (TSGs) have been drugged to date, despite TSG mutations causing 2/3 of all cancer. Here we report a novel 1st-in-class genetically targeted opportunity using BET inhibitors to treat EP300 LoF cancers. Among the hundreds of pharmacogenetic screens that we have conducted, this interaction is similar to PARP-BRCA1/HRD in significance, and among the strongest we have discovered. It is cancer-type agnostic and holds up with all potent BET inhibitors in various pre-clinical models, including PDXs. Mechanistically, we demonstrate that apoptosis induced by DNA catastrophe arising from pre-mature entry into S phase plays a significant role. BET inhibition blocks timely assembly of DNA replication factors, which leads to G1 arrest in healthy cells; cancer cells that lack p300, a key regulator of CDK2, and CDK7, proceed through G1-S before replication deficiencies can be resolved. EP300 loss of function is a causal driver in more than 25,000 new cancer cases per year in the US and there currently are no genetically targeted options for these patients. This presentation will focus on the discovery, characterization, and clinical re-entry plan for our BET inhibitor LFB-190, to treat EP300 LoF solid tumors. Citation Format: Tomas Babak, Peter Truesdell, Greg Vontz, Peter Heinecke, Doris Coto Villa, Meiou Dai. EP300 loss of function is a pan-cancer sensitizer to BET inhibition. [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry; 2024 Dec 9-11; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(12_Suppl):Abstract nr PR002

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.